. "PA824"@en . . . "Investigated for use/treatment in bacterial infection and tuberculosis."@en . . . . . . "187235-37-6"@en . . . . . . . . . . . "PA-824 is a nitroimidazole, a class of novel anti-bacterial agents. As a potential TB therapy, it has many attractive characteristics - most notably its novel mechanism of action, its activity in vitro against all tested drug-resistant clinical isolates, and its activity as both a potent bactericidal and a sterilizing agent in mice. In addition, the compound shows no evidence of mutagenicity in a standard battery of genotoxicity studies, no significant cytochrome P450 interactions, and no significant activity against a broad range of Gram-positive and Gram-negative bacteria."@en . . . . . . "investigational"@en . . . . . . "Although the mechanism of action of PA824 is not well understood, it appears that the compound functions as a prodrug requiring reductive activation of the aromatic nitro group that is mediated, at least in part, by a specific glucose-6-phosphate dehydrogenase or its deazaflavin cofactor."@en . . . .